ENDONOVO THERAPEUTICS, INC. — Net Income by Fiscal Year
13 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/8199a504-683f-4e68-9080-c71ce8220995/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2022 | $-18.5M | 2022-01-01 – 2022-12-31 | evidence 0001493152-23-012553 |
| FY 2021 | $-3.1M | 2021-01-01 – 2021-12-31 | evidence 0001493152-22-009861 |
| FY 2020 | $-395.6k | 2020-01-01 – 2020-12-31 | evidence 0001493152-21-008661 |
| FY 2019 | $-17.3M | 2019-01-01 – 2019-12-31 | evidence 0001493152-20-007577 |
| FY 2018 | $-6.4M | 2018-01-01 – 2018-12-31 | evidence 0001493152-19-005267 |
| FY 2017 | $-10.8M | 2017-01-01 – 2017-12-31 | evidence 0001493152-18-004879 |
| FY 2016 | $-5.3M | 2016-01-01 – 2016-12-31 | evidence 0001493152-17-003917 |
| FY 2015 | $-6.8M | 2015-01-01 – 2015-12-31 | evidence 0001469709-16-000821 |
| FY 2014 | $-959.5k | 2014-01-01 – 2014-12-31 | evidence 0001213900-15-004466 |
| FY 2013 | $-2.9M | 2013-01-01 – 2013-12-31 | evidence 0001213900-15-004466 |
| FY 2012 | $-1.9M | 2012-01-01 – 2012-12-31 | evidence 0001469709-13-000288 |
| FY 2011 | $-94.1k | 2011-01-01 – 2011-12-31 | evidence 0001469709-12-000077 |
| FY 2010 | $-69.4k | 2010-01-01 – 2010-12-31 | evidence 0001469709-12-000077 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
ENDONOVO THERAPEUTICS, INC. — all facts · Revenue · Operating Income